Sung-Yun Pai1, Morton J Cowan. 1. aDivision of Hematology-Oncology, Boston Children's Hospital bDepartment of Pediatric Oncology, Dana-Farber Cancer Institute cDepartment of Pediatrics, Harvard Medical School, Boston, Massachusetts dDivision of Pediatric Allergy, Immunology, and Blood and Marrow Transplant, Benioff Children's Hospital, University of California San Francisco, San Francisco, California, USA.
Abstract
PURPOSE OF REVIEW: This review describes recent studies on outcomes after allogeneic hematopoietic cell transplantation for primary immunodeficiency in North America, including severe combined immunodeficiency (SCID), Wiskott-Aldrich syndrome and chronic granulomatous disease. RECENT FINDINGS: Using uniform diagnostic criteria, the Primary Immune Deficiency Treatment Consortium described the baseline characteristics of newly diagnosed infants with SCID in North America. Analysis of outcomes of hematopoietic cell transplantation for SCID in North America from 2000 to 2009 showed that young infants, and older infants without active infection, had excellent survival irrespective of type of donor or transplant approach with regard to conditioning. Although pretransplant conditioning with chemotherapy had a clear and strong negative impact on survival in infants with active infection at the time of transplant, among survivors, conditioning was associated with improved immune reconstitution. However, the potential late effects of conditioning in these infants remain to be characterized. Advances in transplant outcomes for Wiskott-Aldrich syndrome and chronic granulomatous disease support the strategy of early transplantation before the onset of severe complications; additional multicenter studies are needed to fully define optimal approaches. SUMMARY: The formation of the Primary Immune Deficiency Treatment Consortium, a multiinstitutional North American consortium, has contributed to our understanding of outcomes after transplant for primary immunodeficiency.
PURPOSE OF REVIEW: This review describes recent studies on outcomes after allogeneic hematopoietic cell transplantation for primary immunodeficiency in North America, including severe combined immunodeficiency (SCID), Wiskott-Aldrich syndrome and chronic granulomatous disease. RECENT FINDINGS: Using uniform diagnostic criteria, the Primary Immune Deficiency Treatment Consortium described the baseline characteristics of newly diagnosed infants with SCID in North America. Analysis of outcomes of hematopoietic cell transplantation for SCID in North America from 2000 to 2009 showed that young infants, and older infants without active infection, had excellent survival irrespective of type of donor or transplant approach with regard to conditioning. Although pretransplant conditioning with chemotherapy had a clear and strong negative impact on survival in infants with active infection at the time of transplant, among survivors, conditioning was associated with improved immune reconstitution. However, the potential late effects of conditioning in these infants remain to be characterized. Advances in transplant outcomes for Wiskott-Aldrich syndrome and chronic granulomatous disease support the strategy of early transplantation before the onset of severe complications; additional multicenter studies are needed to fully define optimal approaches. SUMMARY: The formation of the Primary Immune Deficiency Treatment Consortium, a multiinstitutional North American consortium, has contributed to our understanding of outcomes after transplant for primary immunodeficiency.
Authors: R J O'Reilly; B Dupont; S Pahwa; E Grimes; E M Smithwick; R Pahwa; S Schwartz; J A Hansen; F P Siegal; M Sorell; A Svejgaard; C Jersild; M Thomsen; P Platz; P L'Esperance; R A Good Journal: N Engl J Med Date: 1977-12-15 Impact factor: 91.245
Authors: Corinne Antoine; Susanna Müller; Andrew Cant; Marina Cavazzana-Calvo; Paul Veys; Jaak Vossen; Anders Fasth; Carsten Heilmann; Nicolas Wulffraat; Reinhard Seger; Stéphane Blanche; Wilhelm Friedrich; Mario Abinun; Graham Davies; Robert Bredius; Ansgar Schulz; Paul Landais; Alain Fischer Journal: Lancet Date: 2003-02-15 Impact factor: 79.321
Authors: R Parkman; J Rappeport; R Geha; J Belli; R Cassady; R Levey; D G Nathan; F S Rosen Journal: N Engl J Med Date: 1978-04-27 Impact factor: 91.245
Authors: Yao Ding; John D Thompson; Lisa Kobrynski; Jelili Ojodu; Guisou Zarbalian; Scott D Grosse Journal: J Pediatr Date: 2016-02-11 Impact factor: 4.406
Authors: Juliana Folloni Fernandes; Samantha Nichele; Liane E Daudt; Rita B Tavares; Adriana Seber; Fábio R Kerbauy; Adriana Koliski; Gisele Loth; Ana K Vieira; Luiz G Darrigo-Junior; Vanderson Rocha; Alessandra A Gomes; Vergílio Colturato; Luiz F Mantovani; Andreza F Ribeiro; Lisandro L Ribeiro; Cilmara Kuwahara; Ana L M Rodrigues; Victor G Zecchin; Beatriz T Costa-Carvalho; Magda Carneiro-Sampaio; Antonio Condino-Neto; Anders Fasth; Andrew Gennery; Ricardo Pasquini; Nelson Hamerschlak; Carmem Bonfim Journal: J Clin Immunol Date: 2018-11-24 Impact factor: 8.317
Authors: Eun Sang Yi; Young Bae Choi; Na Hee Lee; Ji Won Lee; Ki Woong Sung; Hong Hoe Koo; Eun-Sook Kang; Yae-Jean Kim; Keon Hee Yoo Journal: J Clin Immunol Date: 2018-08-27 Impact factor: 8.317
Authors: Dylan Lawless; Christoph B Geier; Jocelyn R Farmer; Hana Lango Allen; Daniel Thwaites; Faranaz Atschekzei; Matthew Brown; David Buchbinder; Siobhan O Burns; Manish J Butte; Krisztian Csomos; Sri V V Deevi; William Egner; Stephan Ehl; Martha M Eibl; Olajumoke Fadugba; Zsofia Foldvari; Deanna M Green; Sarah E Henrickson; Steven M Holland; Tami John; Christian Klemann; Taco W Kuijpers; Fernando Moreira; Alexander Piller; Paula Rayner-Matthews; Neil D Romberg; Ravishankar Sargur; Reinhold E Schmidt; Claudia Schröder; Catharina Schuetz; Svetlana O Sharapova; Ken G C Smith; Georgios Sogkas; Carsten Speckmann; Kathleen Stirrups; Adrian J Thrasher; Hermann M Wolf; Luigi D Notarangelo; Rashida Anwar; Joan Boyes; Boglarka Ujhazi; James Thaventhiran; Jolan E Walter; Sinisa Savic Journal: J Allergy Clin Immunol Date: 2018-03-02 Impact factor: 10.793